Supplementary Table 1: Search strategy used in Google. SS = self-sample provider, ST = self-test provider. For each search (1-5) the search terms for each concept were combined with the Boolean operator AND. When the acronyms STI (sexually transmitted infection) and STD (sexually transmitted disease) were included in their full form, results were mainly educational or medical, so they were not included in the search. The results for each were listed and pooled to produce a final list of providers. Amazon search terms were similar, but searches were run individually without Boolean operators. The first 5 pages of Google were searched. The search was run on 27/06/2020.

Supplementary Table 1

Search Number	Se	earch Concepts (combined with A	ND)	Number of Providers
	Online	STI	Test	Identified by Google
1	home OR online OR instant OR rapid	sti OR std	test	20 (15 SS, 5 ST)
2	home OR online OR instant OR rapid	chlamydia OR gonorrhoea OR syphilis OR hiv OR herpes	test	16 (11 SS, 5 ST)
3	home OR online OR instant OR rapid	sti OR std	test OR diagnosis OR diagnostic	19 (15 SS, 4 ST)
4	home OR online OR instant OR rapid	chlamydia OR gonorrhoea OR syphilis OR hiv OR herpes	test OR diagnosis OR diagnostic	16 (11 SS, 5 ST)
5	home OR online OR instant OR rapid	sti OR std OR chlamydia OR gonorrhoea OR syphilis OR hiv OR herpes	test OR diagnosis OR diagnostic	13 (11 SS, 2 ST)

Supplementary data 2 - Questionnaires

Questionnaires were adapted to each provider, depending on the tests they provide and the information already available. For questions pertaining to specific test details, and where providers had more than one test, all tests were listed where the template specifies [Test Name/Pathogen]. All questionnaires included the following consent statement:

Dear Sir/Madam.

Thank you for taking part. The information collected during this survey will be used in a research project investigating the quality and availability of online tests for sexually transmitted infections (STIs), taking place at the London School of Hygiene & Tropical Medicine.

This survey is in reference to your diagnostic test [test description and website link]. By providing information, you are consenting to have that information included in this project. No identifying information such as the company name will be included in any published work, and any information collected will be securely stored by the study team. If you wish to withdraw consent at any time after completing the survey, please e-mail [e-mail address] (study lead).

The survey is separated into three parts, 1) pre-test information 2) test performance and 3) post-test information. All questions are optional.

You may also reply in email or document form to [e-mail address] if you would prefer, and do not hesitate to email any questions about the survey or the project.

2a: Self-Test Provider Questionnaire

	Question Text	Answer Options
1	Is the [test details]	□Yes
	suitable for someone who has	□No
	symptoms of an	□Other (Please Specify)
	STI?	Lotter (Ficase openity)
2	Is the [test details]	□Yes
	suitable for home	
	use by someone	
	who is not a clinical	□No
	professional?	
	professionars	
3	What window	Window Period (days)
	period (time	
	between being	
	infected and the	[Test Free text
	infection being	Name/Pathogen]
	detectable by the	
	test) do you	
	advise before	
	using the [test	
_	detail]	Free And
4	What accreditation does	Free text
	your test have	
	(e.g. CE mark, ISO)?	
	100):	

	Suppleme	ntary Material							
5	What specimen does your test		Urine (male)	Urine (female)	Vaginal Swab	Cervical Swab	Blood	Urethral Swab	Other
	require? (Tick all	[Test							Free
6	that apply) Please describe the target and mechanism used for your diagnostic	Name/Pathogen]	pathoger antibody		et for this antigen,	flow immuno	l mechanism of ochromatograp		text g. lateral
	test	[Test Name/Pathogen]	Free text	t		Free text			
7	Please provide information on the specificity and sensitivity of your test and how it was calculated.		Sample Type	Sensitivity (%)	Sensitivity Calculation	Specificity (%)	Specificity Calculation	Referenc	e Test
	For reference: Sensitivity = true positives/true positives + false negatives Specificity = true negatives/true negatives/true negatives + false positives f you do not have access to this information please discuss it with someone who does, or provide their details and we can contact them directly. If it is easier to provide this in document form, please email it to [student email address]	[Test Name/Pathogen]	Free text	Free text	Free text	Free text	Free text	Free text	
8	Please provide details of any publications or other literature describing the test's use and/or performance:	Free text							
9	What advice is given to the user after a negative test result?	Free text							
10	If a test is positive, what advice is given to the user for the next stage of care? (e.g. confirmatory tests, treatment options, follow up with medical professional)	Free text							
11	If a diagnosis is positive, what advice is given in regard to partner notification	Free text							

	(including look back period)?	
12		Free text
13	Is there any other information you would like to include?	Free text

2b: Self-Sample Provider Questionnaire

	Question Text	Answer Options					
1	Are any checks of	□Yes					
	eligibility done	□No					
	before providing a	If yes, please prov	ide details:				
	test to ensure the	Free text					
	test is appropriate						
	to the user (e.g. a						
	patient						
	questionnaire						
	relating to						
	symptoms, risk						
	behaviours or previous						
	diagnoses)?						
2	Is your service	□Yes					
_	suitable for users	□163					
	that have						
	symptoms of an	□No					
	STI?						
3	What national	Free text					
	guidelines do you						
	follow for running						
	your service (e.g.						
4	BASHH)? What window		Mindow Davied	/daa\			
4	period (time		Window Period	(days)			
	between being	\sim					
	infected and the						
	infection being	ſTest	Free text				
	detectable by the	Name/Pathogen]					
	test) do you	0 1					
	advise before						
	using the [test						
	detail]						
5	What laboratory	Free text					
	do you use for						
	your diagnostic						
	tests and what						
	accreditations do						
	they have (e.g. UKAS, ISO)?						
6	Which of the	Mycoplasma	Mycoplasma	Ureaplasma	Ureaplasma	Ureaplasma (not	Other
٠	following species	hominis	genitalium	parvum	urealyticum	species specific)	Otrici
	of Mycoplasma			,			
	and Ureaplasma						Free text
	do you test for?						
7		П.V					
7	Do any of your tests include	☐ Yes					
	antimicrobial	□ No					
	antimorobiai	L INO					

	susceptibility testing?	If yes, please provid	e details: /	Free text							
8 \ t t	What samples do you use to test for the following pathogens in the		Urine (male)	Urine (female)	Oral Swab	Rectal Swab	Vaginal Swab	Cervical Swab	Blood	Urethral Swab	Other
r	[test package name]? Tick all that apply.	[Test Name/Pathogen]									Free text
t F	Please describe the target and platform/assay used for your			he diagnos oody, nucle		l for this pa	I thogen?	What platforthis test?	orm or as	say is used	to run
a ii	diagnostic tests. If any tests are done in combination, or if there are multiple tests used, please include that in the details. If you do not have access to this information, please discuss it with someone who does or provide their details and we can contact them directly. For HIV, please also specify the generation of test if applicable.	[Test Name/Pathogen]	Free text					Free text			
i	Please provide information on the specificity and sensitivity of your		Sample Type	Sensitivit	y (%)	Sensitivit Calculati		Specificit y (%)	Specific y Calcula on		ence
t vv FF S FF F	test and how it was calculated. For reference: Sensitivity = true positives/true positives + false negatives Specificity = true negatives/true negatives/true negatives/true negatives + false positives If you do not have access to this information please discuss it with someone who does, or provide their details and we can contact them directly. If it is easier to provide this in document form, please email it to [student email address]	[Test Name/Pathogen]	Free text	Free text		Free text		Free text	Free te	xt Free to	ext

11	Please provide	Free text		
	details of any			
	publications or			
	other literature			
	describing the			
	test's use and/or			
	performance:			
12	What advice is	Free text		
	given to the user			
	after a negative			
	test result?			
13	What is the next		Next stage of care	Advice/recommendations about
. •	stage of care		. Toke stage of oar o	partner notification
	when the user			partitor fromtoation
	tests positive for			
	the infections	[Test Name/Pathogen]	Free text	Free text
	listed below (e.g.	[restriament amogen]	7.00 (5.1)	. red text
	treatment is			
	provided online,			
	user is referred to			
	a sexual health			
	clinic,			
	confirmatory			
	testing is			
	required), and			
	what advice about			
	partner notification			
	is given (including			
	look back period)?			
14	Do you	☐ Yes		
14	recommend any	□ Tes		
	tests be repeated	□ No		
	at a later date?			
			recommendations are made: Free text	
15	If a chlamydia test	Free text		
	is positive, what is			
	your advice to the			
	user regarding			
	testing for			
	lymphogranuloma			
16	venereum (LGV)? Please describe	Free text		
10	any other advice	riee lext		
	given after a			
	positive diagnosis			
	from any of your			
	tests:			
17	Do you report	□ Yes		
	your results to any	1.33		
	external body			
	(e.g. Public Health	□ No		
	England) for			
	surveillance	If yes, please provide details: Free te	ext	
	purposes?			
10		For a hard		
18	Is there any other	Free text		
	information you			
	would like to			
	include?			

Providers were compared to pathogen specific guidelines where available, and other literature where guidelines have not been published: chlamydia[1], gonorrhoea,[2] syphilis,[3] HIV,[4] hepatitis,[5] herpes,[6] trichomoniasis,[7] Mycoplasma genitalium,[8] Mycoplasma hominis,[9,10] Ureaplasmas,[9,10] Gardnerella,[11] chancroid,[12] human papillomavirus,[13,14] yeasts.[15].

Supplementary Table 3a: Description of the characteristics of self-test kits for sexually transmitted infections found available online. All products were paid for. In total, 9 providers were identified by Amazon search and 4 were identified by both Google and Amazon search.

Provider	Source	Infection	Sample Type Requested	Positive Diagnosis Advice	Professional Use Only?	Accreditation	Sensitivity (sample type)	Specificity (sample type)	Reference Test
1*	В	HIV	Blood	Consult a doctor for confirmatory testing	No	CE, WHO approved	100% (Blood)	99.8% (Blood)	PCR
		Chlamydia	Cervical/urethral swab/Urine		Yes	CE	91.3% (Swab/Urine)	98.1% (Swab/Urine)	PCR
2*	Α	Gonorrhoea	Cervical/urethral swab	Seek confirmatory testing and treatment for you and your partner	Yes	CE	97% (Swab)	96% (Swab)	Culture
		Trichomonia sis	Vaginal	and your parmer	Yes	CE	85.7% (Swab)	97.5% (Swab)	Another rapid test (Unnamed)
		Syphilis	Blood		Yes	CE	99.7% (Blood)	>99.9% (Blood)	TPPA
		Chlamydia	Cervical/urethral swab/urine		Yes	CE	90% (Cervical Swab) 80.9% (Male Urethral Swab) 92.3% (Male Urine)	96.5% (Cervical Swab) 94.3% (Male Urethral Swab) >99.9% (Male Urine)	PCR
		Syphilis	Blood		Yes	CE	>99.9% (Whole Blood)	99.7% (Whole Blood)	/
3	В	Gonorrhoea	Cervical/urethral swab	1	Yes	CE	90.9% (Cervical Swab) 90% (Male Urethral Swab)	96.4% (Cervical Swab) 96.8% (Male Urethral Swab)	Culture
		Hepatitis B Surface Antigen	Blood		Yes	1	>99.9% (Whole Blood)	99.3% (Whole Blood)	/
	_	Hepatitis C	Blood		/	/	99.1% (Whole Blood)	99.5% (Whole Blood)	/

Provider	Source	Infection	Sample Type Requested	Positive Diagnosis Advice	Professional Use Only?	Accreditation	Sensitivity (sample type)	Specificity (sample type)	Reference Test
		HIV Antigen/antib ody	Blood		Yes	1	>99.9%	99.5%	/
4	В	Chlamydia	Cervical Swab (advertised as vaginal)	See a health professional	No	CE	85.7% (Cervical Swab)	98.3% (Cervical Swab)	PCR
		Chlamydia	Swab (source unclear)		Yes	CE, FDA	98.5%	"accurate"	1
		Gonorrhoea	Swab (source unclear)	Coo o booleb	Yes	CE, FDA	98.5%	"accurate"	/
5	Α	Genital Herpes (HSV2)	Blood	See a health professional	Yes	CE, FDA	99% "	accurate"	/
		Oral Herpes (HSV1)	Blood		Yes	CE, FDA	99% "	accurate"	/
		Trichomonia sis	Vaginal swab		Yes	CE, FDA	98.5%	"accurate"	/
		Chlamydia	Cervical/urethral swab/urine		Yes	CE	/	1	/
		Gonorrhoea	/		Yes	CE	/	/	/
		Syphilis	Blood		Yes	CE	/	/	/
		HIV (Blood)	Blood		Yes	WHO Prequalified	/	1	/
6	Α	HIV (Oral)	Oral transudate	/	Yes	/	/	/	/
		Hepatitis B Surface Antibody Hepatitis B	Blood		Yes	/	97.30%	99.20%	1
		Surface Antigen	Blood		Yes	/	1	/	/
		Hepatitis C	Blood		Yes	/	99%	99.80%	/
7*	Α	Trichomonia sis	Vaginal swab	See a health professional	No	CE	99%	100%	Culture
8		Chlamydia	/	1	No	CE	/	/	/
	A	Syphilis	Blood		No -	/	/	/	/

Provider	Source	Infection	Sample Type Requested	Positive Diagnosis Advice	Professional Use Only?	Accreditation	Sensitivity (sample type)	Specificity (sample type)	Reference Test
		Gonorrhoea	Swab (source unclear)		Yes	CE	/	/	/
		HSV1	Blood		Yes	CE	/	/	/
		HSV2	Blood		Yes	CE	/	1	/
9	Α	Chlamydia	Vaginal swab	/	No	/	98.3%	/	/
10*	Α	Chlamydia	Cervical Swab (advertised as vaginal)	See a health professional	No	CE	85.7 % (Cervical Swab)	98.3 % (Cervical Swab)	PCR
11	Α	HIV	Blood	See a health professional for confirmatory tests	No	CE	99.6% (Blood)	/	/
12	Α	HIV	Blood	See a health professional for confirmatory tests	No	CE	99.7% (Blood)	99.9% (Blood)	Enzyme immunoassa y and western blot
		Gardnerella	/		No	/	98.5%	98.6%	PCR
13	В	Trichomonia sis	/	/	No	/	100%	99%	Wet mount microscopy and culture
		Candida Albicans	1		No	1	95.5%	98.4%	Wet mount microscopy and culture

/ Indicates the information was not stated or unclear. HSV = herpes simplex virus, TPPA = Treponema pallidum particle agglutination assay, FDA = food and drug administration, WHO = World Health Organisation. * Indicates the provider responded to the survey. Source indicates Amazon (A), Google (G) or both (B). Accreditation may have been present but the documents not immediately available to us

Supplementary Table 3b: Description of the characteristics of self-sample provider websites and services. In total, 17 providers were identified by Google search and one was identified by both Google and Amazon search. All free providers were commissioned by the National Health Service

Provider	Source	Window Period Stated	Advised for symptomatic users?	Pre-test Screen	Symptom Information	Transmission Information	Health Protection Information	HIV PEP signpost	Positive Result Guidance	Accreditations	Price Range
14	G	Yes	Unclear	No	Yes	Inconsistently	Condoms mentioned on two test pages, not all	Yes	Treat online or arrange a consultation	cqc	£29-£244
15	G	Yes	Unclear	No	Yes	Inconsistently	Thorough description on one test page but not all	Yes	Treat online or arrange a consultation	CQC	£27.99- £225.99
16	G	Yes	No	Yes	Yes, not on the test page	Yes, not on the test page	Yes, not on the test page	Yes	Treat online or referral	Unclear	£27.99-£99.95
17*	G	Yes	No	Yes	Yes	Yes	Yes	Yes	Refer to treatment	CQC, Claims a UKAS Accredited Laboratory	Free
18	G	Yes	No	Yes	Yes	Yes	Yes	Yes	Treat online/referral	Unclear	£28-£128
19	G	Yes	No	Yes	Yes	Yes	Yes	Yes	Treat online/referral	CQC, UKAS accredited laboratory	Free
20	G	Yes	Unclear	No	Yes, not on the test page	Yes, not on the test page	Condoms mentioned on one test page, not all	No	Treat online, consultation or referral	Unclear – UKAS badge given for quality management service, not tests provided	£35-£299
21	G	No	No	No	Yes, not for all pathogens	Yes, not for all pathogens	Links to Wikipedia	No	Signpost to local services	CQC, UKAS accredited laboratory but not accredited for all pathogens tested for	£19.99- £114.99

Provider	Source	Window Period Stated	Advised for symptomatic users?	Pre-test Screen	Symptom Information	Transmission Information	Health Protection Information	HIV PEP signpost	Positive Result Guidance	Accreditations	Price Range
22	G	Yes	Yes	No	No	No	No	No	Results will be discussed with the user	Unclear	£49-£209
23	G	Yes, not for all pathogens	Yes	No	Yes, not on the test page	Yes, not on the test page and not for all pathogens	No	No	Treat online or a consultation or referral	CQC	£29.95- £299.95
24	G	Yes, not for all pathogens	Unclear	Limited	Yes, not for all pathogens and not always on the test page	Yes, not for all pathogens and not always on the test page	Condoms and safe toy use mentioned on each STI info page	No	Phone consultation	Claim they use a UKAS accredited laboratory but no further details to verify this	£95-£239
25*	G	Yes	Yes (survey), No (website)	Yes	Yes	Yes	Yes	Yes	Consultation	Unclear	Free
26	G	Yes, not for all pathogens	Unclear	No	Yes	Yes	No	No	Unclear	CQC, UKAS accredited laboratory	Free
27	В	No	Unclear	No	Yes, not for all pathogens	Yes, not for all pathogens	No	No	Consultation	cqc	£34-£225
28	G	Yes, not for all pathogens	Yes	No	Yes, not for all pathogens	Yes, not for all pathogens	No	No	Advised to see your doctor, states they will not diagnose or consult	CQC, claims UKAS laboratory however this lab is not accredited for all STIs. May be accredited for other services they provide	£37-£251
29	G	Yes	Unclear	No	Yes, not for all pathogens	No	Condoms advised	N/A (no HIV test)	Treat online/referral	CQC	£35

Provider	Source	Window Period Stated	Advised for symptomatic users?	Pre-test Screen	Symptom Information	Transmission Information	Health Protection Information	HIV PEP signpost	Positive Result Guidance	Accreditations	Price Range
30	G	Yes	Unclear	No	Inconsistently	Yes, not for all pathogens	Condoms and safe toy usage mentioned on some pages but not all	Yes	Treat online/referral	cqc	£32-£200
31*	G	Yes	No	Yes	Yes	Yes	Yes	Yes	Treat online/referral	CQC, UKAS Accredited Laboratory	Free

CQC = care quality commission, PEP = post-exposure prophylaxis, ISO = international organisation for standardization, UKAS = United Kingdom Accreditation Service. * indicates that the provider responded to the survey. Source indicates Amazon (A), Google (G) or both (B). Accreditation may have been present but the documents not immediately available to us

- Nwokolo NC, Dragovic B, Patel S, *et al.* 2015 UK national guideline for the management of infection with Chlamydia trachomatis. *Int J STD AIDS* 2015;27:251–67. doi:10.1177/0956462415615443 Available at: https://pubmed.ncbi.nlm.nih.gov/26538553/
- Fifer H, Saunders J, Soni S, *et al.* 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae. *Int J STD AIDS* 2019;31:4–15. doi:10.1177/0956462419886775 Available at: https://pubmed.ncbi.nlm.nih.gov/31870237/
- Kingston M, French P, Higgins S, *et al.* UK national guidelines on the management of syphilis 2015. *Int J STD AIDS* 2015;27:421–46. doi:10.1177/0956462415624059 Available at: https://pubmed.ncbi.nlm.nih.gov/26721608/
- 4 Palfreeman A, Sullivan A, Rayment M, *et al.* British HIV Association/British Association for Sexual Health and HIV/British Infection Association adult HIV testing guidelines 2020. *HIV Med* 2020;21 Suppl 6:1–26. doi:10.1111/hiv.13015 Available at: https://pubmed.ncbi.nlm.nih.gov/33333625/
- British Association for Sexual Health and HIV. 2017 Interim Update of the 2015 BASHH National Guidelines for the Management of Viral Hepatitides. 2017. Available at: https://www.bashhguidelines.org/media/1161/viral-hepatitides-2017-update-18-12-17.pdf (Accessed June 2021)
- Patel R, Green J, Clarke E, et al. 2014 UK national guideline for the management of anogenital herpes. Int J STD AIDS 2015;26:763–76. doi:10.1177/0956462415580512 Available at: https://pubmed.ncbi.nlm.nih.gov/25861804/
- 7 Sherrard J, Ison C, Moody J, *et al.* United Kingdom National Guideline on the Management of Trichomonas vaginalis 2014. *Int J STD AIDS* 2014;25:541–9. doi:10.1177/0956462414525947 Available at: https://pubmed.ncbi.nlm.nih.gov/24616117/
- Soni S, Horner P, Rayment M, *et al.* British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium (2018). *Int J STD AIDS* 2019;30:938–50. doi:10.1177/0956462419825948 Available at: https://pubmed.ncbi.nlm.nih.gov/31280688/
- Horner P, Donders G, Cusini M, *et al.* Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? a position statement from the European STI Guidelines Editorial Board. *J Eur Acad Dermatology Venereol* 2018;32:1845–51. doi:10.1111/jdv.15146 Available at: https://pubmed.ncbi.nlm.nih.gov/29924422/
- Taylor-Robinson D, Horner P, Pallecaros A. Diagnosis of some genital-tract infections: part 2. Molecular tests and the new challenges. *Int J STD AIDS* 2020;31:198–207. doi:10.1177/0956462419890526 Available at: https://pubmed.ncbi.nlm.nih.gov/32009570/
- British Association for Sexual Health and HIV. UK National Guideline for the Management of Bacterial Vaginosis 2012. 2012. Available at: https://www.bashhguidelines.org/media/1041/bv-2012.pdf (Accessed June 2021)
- Lautenschlager S, Kemp M, Christensen JJ, *et al.* 2017 European guideline for the management of chancroid. *Int J STD AIDS* 2017;28:324–9.

doi:10.1177/0956462416687913 Available at: https://pubmed.ncbi.nlm.nih.gov/28081686/

- British Association for Sexual Health and HIV. UK National Guidelines on the Management of Anogenital Warts 2015. 2015. Available at: https://www.bashhguidelines.org/media/1075/uk-national-guideline-on-warts-2015-final.pdf (Accessed June 2021)
- Public Health England. Cervical screening: programme overview. 2021. Available at: https://www.gov.uk/guidance/cervical-screening-programme-overview (Accessed June 2021)
- Saxon C, Edwards A, Rautemaa-Richardson R, *et al.* British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019). *Int J STD AIDS* 2020;31:1124–44. doi:10.1177/0956462420943034 Available at: https://pubmed.ncbi.nlm.nih.gov/32883171/